AMH Equity’s Harvard Bioscience HBIO Stock Holding History

AMH Equity’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.77M	Buy	404,754 +53,884	+15%	+$256K	2.21%	15
2025 Q2	$1.56M	Buy	350,870 +12,134	+4%	+$50.7K	2.05%	20
2025 Q1	$1.92M	Buy	338,736 +88,736	+35%	+$1.14M	2.89%	8
2024 Q4	$5.28M	Buy	250,000 +11,113	+5%	+$255K	5.19%	6
2024 Q3	$6.43M	Buy	238,887 +18,895	+9%	+$557K	8.15%	3
2024 Q2	$6.27M	Sell	219,992 -12,428	-5%	-$436K	8.31%	3
2024 Q1	$9.85M	Buy	232,420 +16,131	+7%	+$725K	9.66%	3
2023 Q4	$11.6M	Buy	216,289 +2,154	+1%	+$97.2K	10.39%	2
2023 Q3	$9.21M	Buy	214,135 +14,135	+7%	+$652K	10.12%	3
2023 Q2	$11M	Sell	200,000 -5,391	-3%	-$296K	12.55%	2
2023 Q1	$8.63M	Sell	205,391 -20,000	-9%	-$593K	9.89%	3
2022 Q4	$6.24M	Buy	225,391 +63,313	+39%	+$1.56M	9.26%	3
2022 Q3	$4.15M	Buy	162,078 +37,078	+30%	+$1.23M	6.26%	4
2022 Q2	$4.5M	Buy	125,000 +47,375	+61%	+$2.14M	7.77%	4
2022 Q1	$4.82M	Sell	77,625 -2,375	-3%	-$140K	5%	8
2021 Q4	$5.64M	Buy	+80,000	New	+$5.69M	7.84%	6

Other funds holding HBIO

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return

AMH Equity's HBIO Position: Q3 2025 in Review

AMH Equity increased its Harvard Bioscience (HBIO) stake by 15% in Q3 2025, buying an estimated $256K and bringing the position to 404,754 shares worth $1.77M. The position accounts for 2.21% of the portfolio, ranked #15.

AMH Equity first reported a position in HBIO in Q4 2021 and has held it in 16 quarters since. The position peaked at $11.6M in Q4 2023. 59 funds tracked by Wall St. Rank hold HBIO as of Q3 2025.

AMH Equity held 404,754 shares of Harvard Bioscience worth $1.77M as of Q3 2025.
AMH Equity bought 53,884 Harvard Bioscience shares in Q3 2025, an estimated $256K.
Harvard Bioscience made up 2.21% of AMH Equity's portfolio in Q3 2025, its #15 holding.
AMH Equity first reported a position in Harvard Bioscience in Q4 2021 and has held it in 16 quarters since.
AMH Equity's Harvard Bioscience position peaked at $11.6M in Q4 2023.
59 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2025.

Based on AMH Equity's 13F filing for Q3 2025, filed 29 Oct 2025.